BioMolecular Imaging can help your company navigate the complexities of biomarker development from preclinical research to FIH imaging to approval. We can guide you as you interface with the FDA, CRO’s, and academic imaging sites.
We help you answer some of the most difficult questions like how to de-risk late phase studies by using imaging to gain certainty that a drug candidate has target bioavailability and the required pharmacokinetics is sound science and solid business practice.
BioMolecular Imaging has provided expert advice to corporations and biotech companies across the spectrum of organ systems, molecular targets, molecular probe constructs, and radioisotopes. These extend from early clinical to late clinical to post-approval strategies in clinical roll-out, company acquisitions, clinical indications, and companion diagnostic